Medical Oncology Physician - 207RX0202X
Customize your policy alerts
Sign up for Medical Oncology Physician - 207RX0202X policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
An internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer.
| Field | Value |
|---|---|
| Code | 207RX0202X |
| Grouping | Allopathic & Osteopathic Physicians |
| Classification | Internal Medicine |
| Specialization | Medical Oncology |
| Category | Individual |
NPI Registrations
8.8K NPIs are registered under this taxonomy code nationwide.
The table below splits that total by NPI type — Type 1 covers individual practitioners, Type 2 covers organizations and facilities — followed by the five states with the most NPIs registered under this taxonomy code.
Medicare: Top Billing Codes by Claims
Medicare claims nationally billed by providers whose primary NUCC taxonomy is this code, broken down by billing code. This is a narrower population than the NPI Registrations count above, which includes providers holding this code as a secondary specialty — the two sections are not directly comparable. Source: CMS Medicare Physician & Other Practitioner by Provider and Service data.
504 rows
| Code | Description | Avg Paid | Claims |
|---|---|---|---|
| Q0138 | Q0138 – Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | $0 | 14.1M |
| J9271 | J9271 – Injection, pembrolizumab, 1 mg | $43 | 7.8M |
| J1439 | J1439 – Injection, ferric carboxymaltose, 1 mg | $1 | 6.7M |
| J1756 | J1756 – Injection, iron sucrose, 1 mg | $0 | 4.5M |
| J0897 | J0897 – Injection, denosumab, 1 mg | $18 | 4.2M |
| Q5101 | Q5101 – Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | $0 | 3.4M |
| J0185 | J0185 – Injection, aprepitant, 1 mg | $1 | 3.3M |
| J0881 | J0881 – Injection, darbepoetin alfa, 1 microgram (non-esrd use) | $2 | 3M |
| J9299 | J9299 – Injection, nivolumab, 1 mg | $23 | 2.8M |
| J1453 | J1453 – Injection, fosaprepitant, 1 mg | $0 | 2.7M |
Showing 1–10 of 504
Medicare: Top Providers by Revenue
The highest-revenue Medicare providers whose primary NUCC taxonomy is this code. This list can overlap with the Medicaid list below — a provider can rank highly in both programs.
Medicaid: Revenue by Year
Medicaid: Top Billing Codes by Claims
Medicaid claims billed by providers whose primary NUCC taxonomy is this code, broken down by state. This is a narrower population than the NPI Registrations count above, which includes providers holding this code as a secondary specialty — the two sections are not directly comparable. Source: state Medicaid claims data.
427 rows
| Code | Description | Avg Paid | Claims |
|---|---|---|---|
| 99214 | 99214 – The provider sees an established patient for an office visit or other outpatient visit invol… | $42 | 746.7K |
| 85025 | 85025 – A complete blood count (better known as a CBC) is a blood test request by a doctor that prov… | $33 | 710.8K |
| 36415 | 36415 – In this procedure, the provider inserts a needle into a vein to collect a blood sample. | $45 | 452.4K |
| 99213 | 99213 – The provider sees an established patient for an office visit or other outpatient visit invol… | $46 | 366.7K |
| 80053 | 80053 – The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures t… | $43 | 236.4K |
| 96413 | 96413 – Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chem… | $69 | 116.9K |
| 99215 | 99215 – The provider sees an established patient for an office visit or other outpatient visit invol… | $62 | 109.1K |
| 99232 | 99232 – The provider sees a patient for a subsequent hospital inpatient or observation care visit in… | $28 | 103.3K |
| 96372 | 96372 – A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via… | $27 | 94.7K |
| S0281 | S0281 – Medical home program, comprehensive care coordination and planning, maintenance of plan | $6 | 85.9K |
Showing 1–10 of 427
Medicaid: Top Providers by Revenue
The highest-revenue Medicaid providers whose primary NUCC taxonomy is this code. This list can overlap with the Medicare list above — a provider can rank highly in both programs.
| Provider | State | Revenue |
|---|---|---|
| FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC | FL | $63.3M |
| NORTHERN CALIFORNIA CANCER CENTER | CA | $40M |
| NORTH PLATTE NEBRASKA HOSPITAL CORPORATION | NE | $9.5M |
| CARIBBEAN CANCER CARE SERVICES, LLC | PR | $6.5M |
| MIAMI HEMATOLOGY AND ONCOLOGY ASSOCIATES LLC | FL | $5.3M |
| CHEYENNE REGIONAL PHYSICIANS GROUP, LLC | WY | $5.1M |
| WEST MICHIGAN CANCER CENTER | MI | $4.7M |
| UTAH CANCER SPECIALISTS PC | UT |
Frequently Asked Questions
References
- 1.NPI Registry. Centers for Medicare & Medicaid Services (CMS), National Plan and Provider Enumeration System (NPPES). Retrieved Aug 11, 2026.The public NPPES lookup tool for verifying a provider's National Provider Identifier, practice address, and taxonomy classification.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.